SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Combining treatments to boost tumor response in lung cancer September 25, 2024 Amputees regain temperature sensation with new prosthetic technology February 9, 2024 Study finds no evidence linking sickle cell trait to sudden death January 31, 2025